How should the basic metabolic panel, complete blood count, and abdominal x‑ray findings be interpreted and managed in an 83‑year‑old woman with recent explosive diarrhea episodes separated by a week, a period of constipation, mild abdominal discomfort, decreased oral intake, transverse myelitis with bladder dysfunction on prophylactic nitrofurantoin, and newly prescribed cholesterol‑lowering medication?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Interpretation and Management of Laboratory Results

In this 83-year-old woman with episodic explosive diarrhea alternating with constipation, the basic metabolic panel, complete blood count, and abdominal x-ray should be interpreted primarily to identify electrolyte depletion from diarrhea-related losses, assess renal function given her chronic nitrofurantoin use, evaluate for fecal impaction with overflow diarrhea, and rule out bowel obstruction—with management focused on correcting any electrolyte abnormalities, ensuring adequate hydration, and addressing the underlying constipation pattern rather than treating isolated diarrhea episodes.

Key Diagnostic Considerations

This clinical presentation does not represent chronic diarrhea (which requires ≥3 loose stools daily for >4 weeks) but rather intermittent explosive diarrhea with intervening constipation—a pattern highly suggestive of fecal impaction with overflow diarrhea 1. The week-long absence of bowel movements between episodes is the critical clue.

Laboratory Interpretation Framework

Basic Metabolic Panel - Priority Findings:

  • Electrolyte abnormalities (particularly hypokalemia, hyponatremia, metabolic acidosis or alkalosis) from diarrheal losses and poor oral intake 2
  • Elevated BUN/creatinine ratio suggesting dehydration versus intrinsic renal dysfunction
  • Renal function assessment is critical given chronic nitrofurantoin use, as renal impairment (creatinine clearance <60 mL/min) significantly increases risk of severe nitrofurantoin toxicity including peripheral neuropathy 3
  • Elevated creatinine may indicate volume depletion from inadequate oral intake and diarrheal losses

Complete Blood Count - Priority Findings:

  • Anemia may indicate chronic disease, malnutrition from poor intake, or rarely nitrofurantoin-induced hemolytic anemia (particularly in glucose-6-phosphate dehydrogenase deficiency) 3
  • Leukocytosis could suggest infectious colitis or Clostridioides difficile infection (CDAD), which is specifically associated with nitrofurantoin use 3
  • Agranulocytosis is a rare but life-threatening nitrofurantoin complication 4
  • Elevated hematocrit may indicate hemoconcentration from dehydration

Abdominal X-ray - Priority Findings:

  • Fecal loading/impaction throughout the colon, particularly in the rectosigmoid region
  • Dilated bowel loops suggesting obstruction versus ileus
  • Air-fluid levels indicating mechanical obstruction
  • Free air (perforation—extremely rare but reported in transverse myelitis patients with severe constipation) 5

Clinical Reasoning and Alarm Features

This patient has multiple alarm features warranting thorough investigation 1:

  • Age >65 years with recent change in bowel habit
  • Decreased appetite and weight loss risk from poor oral intake
  • Underlying neurologic disease (transverse myelitis) predisposing to bowel dysfunction 5
  • New medication (cholesterol-lowering agent—statins can cause diarrhea)

Critical Pitfall: Nitrofurantoin and CDAD

Nitrofurantoin can cause Clostridioides difficile-associated diarrhea, which ranges from mild diarrhea to fatal colitis 3. This must be considered in any patient on nitrofurantoin presenting with diarrhea. If clinical suspicion exists (fever, leukocytosis, severe or persistent diarrhea), stool testing for C. difficile toxin is mandatory even though not part of the basic workup ordered 6, 3.

Management Algorithm Based on Results

If Electrolyte Abnormalities Present:

  • Correct hypokalemia (common with diarrhea): oral or IV potassium replacement depending on severity
  • Correct volume depletion: IV fluids if moderate-severe dehydration or unable to maintain oral intake
  • Monitor closely if metabolic acidosis present (suggests significant diarrheal losses)

If Renal Function Impaired (Creatinine Clearance <60 mL/min):

  • Strongly consider discontinuing nitrofurantoin given increased risk of severe peripheral neuropathy, which may be irreversible 3
  • Alternative UTI prophylaxis should be discussed with her primary provider
  • Assess for early neuropathy signs: paresthesias, numbness, weakness

If Fecal Impaction Confirmed on X-ray:

This is the most likely diagnosis and requires immediate treatment:

  • Manual disimpaction if rectal impaction present
  • Aggressive bowel regimen: polyethylene glycol (PEG) 17g daily, NOT stimulant laxatives initially
  • Avoid antidiarrheal agents (loperamide, diphenoxylate)—these will worsen impaction
  • Address her fear: Explain that the "diarrhea" is actually liquid stool bypassing hard impacted stool, and treating the constipation will prevent future explosive episodes

If Bowel Obstruction Suspected:

  • Surgical consultation immediately
  • NPO status with IV hydration
  • Nasogastric decompression if indicated

If Normal Studies:

  • Stool studies should be added: C. difficile testing, bacterial culture, ova and parasites if diarrhea recurs 1, 6
  • Medication review: newly prescribed statin may cause diarrhea; consider alternative or discontinuation trial
  • Thyroid function testing: hyperthyroidism causes diarrhea 1

Special Considerations for Transverse Myelitis

Patients with transverse myelitis have neurogenic bowel dysfunction that predisposes to severe constipation 5. The case report of fatal intestinal perforation from constipation in transverse myelitis underscores that bowel dysfunction in this population is not benign 5.

Proactive bowel management is essential:

  • Scheduled osmotic laxatives (PEG preferred)
  • Adequate hydration
  • Dietary fiber if tolerated
  • Regular monitoring of bowel patterns

Addressing Patient Concerns

The patient's fear of medications causing recurrent diarrhea is misplaced—her pattern suggests constipation with overflow, not primary diarrhea. Education is critical: explain that treating the underlying constipation will prevent the explosive episodes she fears. Osmotic laxatives like PEG are safe and do not cause the cramping or urgency associated with stimulant laxatives.

Her concern about medication interactions is valid given nitrofurantoin's toxicity profile, particularly with her age, potential renal impairment, and neurologic disease 3. A comprehensive medication review with her primary provider is warranted.

Monitoring and Follow-up

  • Recheck electrolytes in 24-48 hours if abnormal initially
  • Renal function monitoring every 3-6 months on chronic nitrofurantoin 3
  • Bowel diary to track pattern and response to treatment
  • Reassess in 1-2 weeks after initiating bowel regimen

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.